Omburtamab API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Omburtamab API 1895083-75-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Omburtamab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Omburtamab
- Synonyms:
- Cas Number:
- 1895083-75-6
- DrugBank number:
- DB15635
- Unique Ingredient Identifier:
- XQL6783S5T
General Description:
Omburtamab, identified by CAS number 1895083-75-6, is a notable compound with significant therapeutic applications. CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours. Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers. Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases).
Mechanism of Action:
Omburtamab functions by: CD276 (also known as B7-H3) is a member of the B7/CD28 immunoglobulin superfamily with possible co-stimulatory and co-inhibitory roles in T cell-mediated immunity. Despite low to absent expression on most healthy cells, CD276 is frequently highly expressed among solid human tumours. Omburtamab, a murine anti-B7-H3 antibody, and its humanized forms bind to the CD276 FG loop thought to be important in co-inhibitory functions. Omburtamab also facilitates direct antibody-directed cellular cytotoxicity (ADCC) of CD276-expressing tumour cells. Recent experiments using chimeric antigen receptor (CAR) T cells and bispecific killer cell engager (BiKE)-redirected natural killer cells demonstrated efficacy against NSCLC _in vitro_ and _in vivo_. Hence, targeting CD276 appears to be an appealing option for overcoming immunotherapy blockade in solid tumours. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Omburtamab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Omburtamab is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.
